Analysts Expect Travere Therapeutics, Inc. (NASDAQ:TVTX) Will Post Quarterly Sales of $50.20 Million

Equities analysts expect that Travere Therapeutics, Inc. (NASDAQ:TVTX) will post $50.20 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for Travere Therapeutics’ earnings. The highest sales estimate is $50.42 million and the lowest is $50.00 million. Travere Therapeutics reported sales of $48.43 million during the same quarter last year, which indicates a positive year-over-year growth rate of 3.7%. The firm is scheduled to issue its next earnings report on Thursday, July 29th.

On average, analysts expect that Travere Therapeutics will report full-year sales of $199.71 million for the current financial year, with estimates ranging from $192.60 million to $207.60 million. For the next fiscal year, analysts expect that the firm will report sales of $200.34 million, with estimates ranging from $186.13 million to $216.80 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Travere Therapeutics.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, May 6th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.40). The company had revenue of $47.41 million during the quarter, compared to analysts’ expectations of $49.99 million. Travere Therapeutics had a negative return on equity of 75.08% and a negative net margin of 113.21%.

Several analysts recently issued reports on the company. BMO Capital Markets cut their target price on Travere Therapeutics from $43.00 to $38.00 and set an “outperform” rating for the company in a research report on Friday, May 7th. Canaccord Genuity cut their target price on Travere Therapeutics from $48.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, May 24th. SVB Leerink restated a “buy” rating on shares of Travere Therapeutics in a report on Sunday, June 6th. Barclays cut their price target on Travere Therapeutics from $40.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, May 26th. Finally, Zacks Investment Research cut Travere Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, April 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Travere Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $32.71.

In related news, CEO Eric M. Dube sold 9,562 shares of the firm’s stock in a transaction that occurred on Wednesday, June 2nd. The stock was sold at an average price of $14.62, for a total transaction of $139,796.44. 4.31% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TVTX. Janus Henderson Group PLC purchased a new position in Travere Therapeutics during the 4th quarter worth $111,297,000. Armistice Capital LLC purchased a new position in shares of Travere Therapeutics in the 1st quarter valued at $58,829,000. Avoro Capital Advisors LLC purchased a new position in shares of Travere Therapeutics in the 4th quarter valued at $49,073,000. Oak Ridge Investments LLC increased its holdings in shares of Travere Therapeutics by 983.9% in the 1st quarter. Oak Ridge Investments LLC now owns 1,323,149 shares of the company’s stock valued at $33,039,000 after acquiring an additional 1,201,073 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Travere Therapeutics in the 4th quarter valued at $32,481,000.

Shares of NASDAQ:TVTX traded down $0.34 during trading on Monday, hitting $13.40. 10,426 shares of the company’s stock were exchanged, compared to its average volume of 703,376. The company has a debt-to-equity ratio of 0.60, a quick ratio of 6.56 and a current ratio of 6.65. Travere Therapeutics has a 52-week low of $13.24 and a 52-week high of $33.09. The firm has a 50-day moving average of $15.42. The firm has a market capitalization of $810.16 million, a P/E ratio of -3.16 and a beta of 0.67.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

Further Reading: What is the Bid-Ask Spread?

Get a free copy of the Zacks research report on Travere Therapeutics (TVTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.